Compare Hims and Hers Health Inc (HIMS) vs Lockheed Martin Corporation (LMT) Price & Performance

Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.

The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.

Lockheed Martin (LMT) trades at $499.22, down 2.14% over the past day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 18.73 and net income margin of 8.16%, though recent quarters saw mixed earnings results. Revenue growth is steady, reaching $75.05B in 2025, and the company maintains a robust dividend history, recently declaring a $3.45 payout. Analyst consensus remains bullish with a $635.33 price target, supported by ongoing defense spending and strategic initiatives like AI integration and Skunk Works innovation.

Outlook for LMT is positive due to solid defense contracts and technological advancements, but risks include fixed-price contract volatility and competitive pressures. The stock offers value with a below-sector P/E and high institutional confidence, though investors should monitor execution on earnings targets and macroeconomic impacts on defense budgets.